Merck KGaA Expands German Production Facility for Allergopharma Unit - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck KGaA Expands German Production Facility for Allergopharma Unit


Merck KGaA broke ground on a new production facility for its Allergopharma unit in Reinbek near Hamburg, the company announced in a press release. The new facility is estimated to cost nearly € 40 million ($55 million) and will be constructed on the current Allergopharma premises, with completion scheduled for 2016.

The facility will manufacture products for the diagnosis and treatment of type 1 allergies such as hay fever or allergic asthma under ultrapure, sterile conditions. The expansion will be used, among other things, to serve new markets, such as China. The new building will have a surface area of more than 6,000 square meters.

The market for allergy therapies (excluding symptomatic treatments) is showing strong global growth generated by an increasing number of people with allergies and by increasing use of specific immunotherapies in many emerging markets. Global growth is estimated to be between 5% and 10% per year, according to the press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here